Kidney failure

Gold Kidney Health Plan 2024 Medicare Advantage in Arizona and Florida Giving Seniors Affordability, Choice and Freedom

Retrieved on: 
Sunday, October 15, 2023
Dialysis, Hospital, Hearing, Kidney failure, Transport, Freedom, Diabetes, TTY, Medicare, Heart failure, Gold, Life, Health insurance

Expansion into nine Florida counties and continuing our footprint in Arizona will empower more seniors to live a healthier life, while saving money and having more options to choose from

Key Points: 
  • Expansion into nine Florida counties and continuing our footprint in Arizona will empower more seniors to live a healthier life, while saving money and having more options to choose from
    Plus, our extensive network of participating doctors, specialists and hospitals
    SCOTTSDALE, Ariz., Oct. 15, 2023 /PRNewswire/ -- Gold Kidney Health Plan, a Medicare Advantage Plan offering Medicare Advantage products for beneficiaries with Chronic Special Needs, will offer Seniors more options, flexibility and value in 2024.
  • Gold Kidney's product portfolio is one of a kind by tailoring offerings to meet the needs of individuals with chronic conditions that lead to kidney failure, such as diabetes, heart failure, and cardiovascular conditions.
  • They also offer traditional Medicare Advantage plans for non-chronic conditions.
  • * In 2024 all Gold Kidney products offer freedom and flexibility to use in-network and out-of- network providers at the same cost-share.

American Diabetes Association elevates health technology innovation through inaugural event in Silicon Valley

Retrieved on: 
Tuesday, October 3, 2023
Amputation, Kidney failure, Diabetes, Stroke, Ernst & Young, Paratriathlon, Doctor of Philosophy, Royal Bank of Canada, IT Leader Forum, Silicon, BPM, SAN, American Diabetes Association, Showcase, CPA, Association of British HealthTech Industries, Prediabetes, Nerve, ADA, Family, Medtech, National Board of Health and Welfare (Sweden), Disease, Pharmaceutical industry, Video game

The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.

Key Points: 
  • The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.
  • While most of the companies are Silicon Valley/San Francisco Bay Area startups, the event draws applicants from across the country.
  • "The Leaders Forum HealthTech Showcase is what Silicon Valley is about: innovation, technology and progress.
  • "Nearly half of American adults have diabetes or prediabetes, and the impact on the patient, their family, and our society is profoundly underestimated," she continued.

Rimidi to Showcase New Chronic Kidney Disease Module at HLTH 2023, Complementing Suite of Chronic Disease Management Solutions

Retrieved on: 
Tuesday, October 3, 2023
Kidney disease, ESRD, Kidney failure, Chronic kidney disease, Diabetes, Electronic health record, Workflow, Risk, Doctor of Philosophy, KFRE, Dialysis, Hypertension, Triage, Module, MD, EHR, Patient, Death, CKD, Conditional sentence, Nursing, Pharmaceutical industry, Medical imaging

ATLANTA, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, today announced the launch of its new Chronic Kidney Disease (CKD) Module, designed to give providers better visibility on the status of their population of patients with CKD to improve disease management.

Key Points: 
  • Given that Rimidi already supports disease management and remote patient monitoring for diabetes and hypertension, two common risk factors for CKD, developing a full CKD Module was a natural platform progression.
  • Similar to Rimidi's additional chronic disease modules , the CKD Module will combine clinically relevant data from the Electronic Health Record (EHR) with patient-generated data from connected devices and patient surveys into a streamlined, problem-oriented view that allows for better risk stratification and chronic disease management.
  • The KFRE predicts the 5-year risk of end-stage renal disease (ESRD) in patients with chronic kidney disease (CKD) stages 3-5.
  • For more information about Rimidi's Chronic Kidney Disease Module, visit rimidi.com/chronic-kidney-disease or stop by booth #853 at HLTH 2023.

Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care

Retrieved on: 
Tuesday, October 3, 2023
Research, Medical Devices, Medical Supplies, Other Health, Managed Care, General Health, Pharmaceutical, Health, Science, Other Science, Dialysis, CDC, Organization, Rockwell Medical, Kidney failure, The Company, Senior, Patient, Kidney disease, Marketing, Medical device

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement with Centers for Dialysis Care, Inc. ("CDC"), the largest non-profit, independent outpatient dialysis provider in Northeast Ohio.

Key Points: 
  • Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement with Centers for Dialysis Care, Inc. ("CDC"), the largest non-profit, independent outpatient dialysis provider in Northeast Ohio.
  • CDC provides in-center dialysis, home dialysis, training, education support, and nutrition counseling to individuals with kidney disease and kidney failure.
  • "CDC is a leader in providing high-quality, patient-centered kidney health care to all individuals with kidney disease," said Tim Chole , Senior Vice President, Sales and Marketing at Rockwell Medical.
  • "This long-term product purchase agreement reflects our confidence in Rockwell Medical as a supplier," said Michael Humphrey, Director of Procurement at CDC.

Embracing Creativity: Spotlight on Kidney Warriors' Coping Strategies

Retrieved on: 
Friday, September 29, 2023
French landscape garden, Heart, Flower, Happiness, Second Place, Kidney failure, Chronic kidney disease, Power of Three, Cañada, First Place, Enjoy the Moment, Multimedia, Emotion, GA, Mind Games, Creativity, Dialysis, RSN, Essay, Renal Support Network, Third place, CKD, Jump In!, Hartwell, Social media, Kidney disease, Thelma, Creative industries, Entertainment, Toy, Typesetting, Restaurant, Pharmaceutical industry, Love, Gardening

GLENDALE, Calif., Sept. 29, 2023 /PRNewswire-PRWeb/ -- The Renal Support Network (RSN) is thrilled to unveil the talented winners of the 21st annual essay contest. The theme this year was "How do you use your creativity to help cope with kidney disease?" This inspiring competition encouraged individuals living with kidney disease to share their experiences and insights on how creativity has been a vital tool in their coping journey. The contest is open to anyone in the United States who has been diagnosed with chronic kidney disease.

Key Points: 
  • This inspiring competition encouraged individuals living with kidney disease to share their experiences and insights on how creativity has been a vital tool in their coping journey.
  • The contest is open to anyone in the United States who has been diagnosed with chronic kidney disease.
  • The array of heartfelt and imaginative entries from kidney disease warriors across the country demonstrates how creativity can be an effective and a joyful coping strategy.
  • Hartwell suffered kidney failure at the age of two, survived 50+ surgeries and 13 years of dialysis, and is now living with her fourth kidney transplant.

The National Kidney Foundation, Healthy.io and Affinia Healthcare Announce Collaboration to Increase Access to Testing for Kidney Disease in St. Louis, Missouri

Retrieved on: 
Thursday, September 28, 2023
Partnership, Kidney failure, Travel, Chronic kidney disease, Diabetes, FQHC, African Americans, Kidney, Dialysis, Hypertension, Patient, White Americans, NKF, National Kidney Foundation, Diagnosis, FDA, CKD, Healthy.io, Kidney disease, Disease, Pharmaceutical industry, Nursing, 15-minute city

NEW YORK, BOSTON, and ST. LOUIS, Sept. 28, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF), a non-profit health organization dedicated to the awareness, prevention, and treatment of kidney disease and Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced as part of their ongoing partnership a collaboration with Affinia Healthcare, a St. Louis-based federally qualified health center (FQHC). The new program offers Affinia Healthcare patients access to the Minuteful Kidney test, the first FDA-cleared smartphone-powered kidney test to support the identification of chronic kidney disease (CKD). Testing for kidney damage among at-risk populations is important for the detection of CKD, a preventable but highly under-diagnosed condition.

Key Points: 
  • The new program offers Affinia Healthcare patients access to the Minuteful Kidney test, the first FDA-cleared smartphone-powered kidney test to support the identification of chronic kidney disease (CKD).
  • Testing for kidney damage among at-risk populations is important for the detection of CKD, a preventable but highly under-diagnosed condition.
  • Providing solutions that enable convenient and accessible testing across under-represented communities is particularly important as CKD disproportionately affects minority communities.
  • By offering an equitable solution to testing, we will be able to impact lives and communities and improve health results."

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

Retrieved on: 
Tuesday, September 26, 2023
Kidney failure, Jay Traver, SPARTAN, IgA nephropathy, Immunoglobulin A, Proteinuria, International Symposium on Endovascular Therapy, Patient, SAN, Radar, Therapy, Safety, Pharmaceutical industry

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.

Key Points: 
  • SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.
  • The Company will also present preclinical data supporting the nephroprotective mechanism of action of sparsentan, a dual endothelin angiotensin receptor antagonist, and an analysis of the UK National Registry of Rare Renal Diseases (RaDaR) which demonstrated that patients with IgAN traditionally considered ‘low-risk’, with proteinuria less than one gram per day, had high rates of kidney failure.
  • “Patients with IgA nephropathy need both early and effective treatment options capable of significant and sustained reduction of proteinuria to preserve kidney function,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.
  • “We’re pleased to be presenting 24-week data on proteinuria reduction, blood pressure control, and safety from the ongoing SPARTAN Study evaluating the effect of sparsentan as a first-line treatment option in patients with newly diagnosed IgAN.”
    Sparsentan Treatment of Incident Patients With IgA Nephropathy as First-line Therapy: Interim Findings From the SPARTAN Trial

American Kidney Fund Launches Educational Awareness Campaigns for Two Rare Kidney Diseases

Retrieved on: 
Tuesday, September 26, 2023
Infection, Tissue, Kidney failure, AKF, Inflammation, Immunoglobulin A, Kidney, Antibody, Hyperkinesia, C3, New Brunswick neurological syndrome of unknown cause, Novartis, Patient, American Kidney Fund, Blood, Immune system, Glomerulopathy, Diagnosis, Health, Kidney disease, Disease, Pharmaceutical industry, IgA nephropathy

ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN).

Key Points: 
  • ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN).
  • The campaigns, sponsored by Novartis, provide patients with information about the diseases and connect them with resources to help them better understand and manage these conditions.
  • C3G and IgAN are two types of kidney diseases that are related to improper function of the immune system, which is your body's cells and tissues that fight infection.
  • The C3G and IgAN campaigns are part of AKF’s ongoing work to increase awareness and understanding of rare kidney diseases and ensure people with these conditions have access to critical resources.

National Kidney Registry-Sponsored Athlete Earns Guinness World Record for 50 Summits Effort

Retrieved on: 
Monday, September 25, 2023
National Kidney Registry, Kidney, Guinness World Records, Ashley, Liver, Travel, Kidney failure, Guinness, Gannett Peak, Dietary supplement

His accomplishment, which was sponsored by the National Kidney Registry , saw him summit the highest point in all 50 US states in 41 days, 21 hours and 1 minute, besting the previous Guinness World Record by more than one full day.

Key Points: 
  • His accomplishment, which was sponsored by the National Kidney Registry , saw him summit the highest point in all 50 US states in 41 days, 21 hours and 1 minute, besting the previous Guinness World Record by more than one full day.
  • "We're so thrilled that Guinness has acknowledged this remarkable effort," said Michael Lollo, Chief Strategy Officer at the National Kidney Registry.
  • "Having it commemorated with a Guinness World Record will hopefully bring more attention to living kidney donation.
  • He was previously sponsored by the National Kidney Registry when he became the first living kidney donor, living liver donor and double organ donor to climb the seven summits in 2022.

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

Retrieved on: 
Thursday, September 21, 2023
Medicine, Kidney failure, International, Heart Protection Study, CMA, Jay Traver, European Medicines Agency, Clinical trial, EGFR, European Directive on Traditional Herbal Medicinal Products, CSL Vifor, Immunoglobulin A, Dialysis, Committee, EMA, Proteinuria, Conditional, Nephrology, ANCOVA, Shanda, Publication, Patient, Division, Risk, Irbesartan, Kidney transplantation, Webcast, Committee for Medicinal Products for Human Use, FDA, Therapy, PROTECT, Kidney disease, Safety, CHMP, Hydraulic machinery, Medical device, Pharmaceutical industry, EU, IgA nephropathy

This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.

Key Points: 
  • This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.
  • “Since our accelerated approval, we’ve continued to hear inspiring stories of the impact this medicine is having on people living with IgAN.
  • While eGFR total slope narrowly missed statistical significance, the overall evidence from PROTECT suggests potential long-term benefit of FILSPARI as a foundational treatment for patients with IgAN.
  • Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.